NCI SBIR Overview
& Upcoming Funding Opportunities

BioOhio and the National Cancer Institute Small Business Innovation Research (NCI SBIR) Development Center invite you to attend the upcoming seminar to learn about new non-dilutive funding opportunities available for early-stage companies. The session will cover current and upcoming changes to the SBIR & STTR programs, practical strategies for developing successful proposals, other NCI resources offered to accelerate drug development and commercialization, and the latest funding opportunities from other government sources, such as the Department of Defense and BARDA. This event is free to attend.

There are many accounting, tax, and reporting requirements with SBIR/STTR grants. Representatives from CPA firm Brixey & Meyer will be on-site to answer any questions related to the appropriate accounting treatment. Brixey & Meyer is a regional CPA firm with offices in Ohio. They specialize in providing their clients with technical accounting and tax assistance related to grant accounting.


G2G 400


1 – 2 PM – Presentation by Ming Zhao, PhD, Program Director, NCI SBIR Development Center

This session will provide an overview of:

  • Overview of SBIR/STTR eligibility requirements
  • NIH SBIR/STTR process
  • Practical strategies on how to successfully submit competitive research proposals
  • Audience Q&A

2 – 2:15 – Presentation by Liz Powell and Becky Watts, G2G Consulting

This session will provide an overview of:

  • Funding landscape for biosciences beyond SBIRs
  • Key agencies for biosciences to target
  • Timelines to follow
  • Process for applying for non-SBIR grants
  • Case studies in obtaining government funding

2:15 – 5:30 – One-on-one meetings with Dr. Zhao and G2G. Meeting times will be in 15 minute increments.

The opportunity to schedule one-on-one meetings with Dr. Zhao and/or G2G is now closed. BioEnterprise and/or CincyTech will contact applicants to schedule meeting times.

Tuesday, September 5


Global Center for Health Innovation

1 St Clair Ave NE

Cleveland, OH 44114

In Partnership With

BioEnterprise 2014

Wednesday, September 6


Union Hall

1311 Vine St.

Cincinnati, OH 45202

In Partnership With


About the speakers


Ming Zhao, PhD, Program Director, Cancer Diagnostics & Therapeutics, Cancer Control & Prevention, Molecular Imaging, Bioinformatics and Stem Cells, NCI SBIR

Dr. Zhao develops and manages SBIR/STTR programs and contracts focused on cancer therapeutics, molecular diagnostics and medical imaging. Prior to his appointment at SBIR, Dr. Zhao was a Program Director in the Center to Reduce Cancer Health Disparities (CRCHD) at the NCI. During his tenure at CRCHD, he managed various NCI/NIH programs such as Community Networks Program Centers (CNPC, a program with a total of $117M & 23 Centers) and Geographical Management of Cancer Health Disparities Program (GMaP) as well as R01/R21 grants. Before Dr. Zhao joined NCI, he worked as a senior scientist at the GE Global Research Center and as a scientist at Pfizer.


Liz Powell, Esq., MPH, Founder, G2G

Cincinnati Event

Liz is the founder of G2G and an attorney with 20 years government experience, including serving as Legislative Director in Congress. She leads a team of bipartisan professionals based in Columbus, Cleveland and D.C. that has raised over $157M since 2007. G2G has also run advocacy campaigns; written legislation; provided access to DoD, DHS, HHS, CMS, OSTP and other federal departments; shaped CMS reimbursement rates and regulations; and led lobbying efforts in the Statehouse. G2G’s niche is working with bioscience startup and growing businesses and non-profits.


Becky Watts, Government Affairs Manager, G2G

Cleveland Event

Becky has 20 years government experience, including serving as Appropriations Director in Congress for Ohio’s current Attorney General, Mike DeWine when he was a U.S. Senator on the Appropriations Committee. She has also worked in the Statehouse for former Speaker Jo Ann Davidson. Becky is based at G2G’s Cleveland office inside the BioEnterprise building.